Neurodevelopmental Outcomes Following Intravitreal Bevacizumab With Laser Versus Laser Photocoagulation Alone for Retinopathy of Prematurity

被引：10
作者：
Ahmed, Kamran [1 ]
Ali, Anam S. [2 ]
Delwadia, Neil [1 ]
Greven, Margaret A. [1 ]
机构：
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Ophthalmol, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Winston Salem, NC 27157 USA
来源：
OPHTHALMIC SURGERY LASERS & IMAGING RETINA | 2020年 / 51卷 / 04期
关键词：
ENDOTHELIAL GROWTH-FACTOR; LOW-BIRTH-WEIGHT; DEVELOPMENTAL OUTCOMES; BAYLEY-III; VEGF; CHILDREN; THERAPY; PRETERM; SYSTEM; DELAY;
D O I：
10.3928/23258160-20200326-03
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
BACKGROUND AND OBJECTIVE: To assess neurodevelopmental outcomes of infants with treatment-warranted retinopathy of prematurity (TW-ROP) treated with intravitreal bevacizumab (IVB) plus diode laser photocoagulation (DLP) compared to DLP alone. PATIENTS AND METHODS: A retrospective review was performed of infants who underwent treatment for TW-ROP with IVB+DLP or DLP alone from 2010 to 2017. Baseline characteristics and coexisting medical comorbidities were recorded. The presence of neurodevelopmental delay (NDD) at 2-year follow-up and composite Bayley-III scores were recorded. RESULTS: Sixty-six infants were included in the study; 18 received IVB+DLP, and 48 received DLP alone. Average Bayley-III scores for cognition, language, and motor, as well as rates of documental NDD, did not differ between the groups. CONCLUSION: This study does not demonstrate an increased risk of NDD in infants with TW-ROP treated with IVB+DLP compared with DLP alone.
引用
收藏
页码：220 / 224
页数：5
相关论文
共 28 条
[1]   Preliminary Anatomical and Neurodevelopmental Outcomes of Intravitreal Bevacizumab As Adjunctive Treatment for Retinopathy of Prematurity [J].
Araz-Ersan, Bilge ;
Kir, Nur ;
Tuncer, Samuray ;
Aydinoglu-Candan, Ozlem ;
Yildiz-Inec, Dilbade ;
Akdogan, Basri ;
Ekici, Baris ;
Demirel, Atalay ;
Ozmen, Meral .
CURRENT EYE RESEARCH, 2015, 40 (06) :585-591
[2]  
Ballot Daynia E, 2017, Int Sch Res Notices, V2017, P1631760, DOI 10.1155/2017/1631760
[3]   Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016; 123: 1843-1844) [J].
Blair, Michael P. ;
Shapiro, Michael J. .
OPHTHALMOLOGY, 2017, 124 (10) :E74-E75
[4]   Outcomes of Intravitreal Bevacizumab and Diode Laser Photocoagulation for Treatment-Warranted Retinopathy of Prematurity [J].
Chen, Tiffany A. ;
Schachar, Ira H. ;
Moshfeghi, Darius M. .
OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2018, 49 (02) :126-131
[5]   VEGF in the nervous system: an important target for research in neurodevelopmental and regenerative medicine [J].
Dumpich, Matthias ;
Theiss, Carsten .
NEURAL REGENERATION RESEARCH, 2015, 10 (11) :1725-1726
[6]  
Dumpich M, 2015, CURR NEUROVASC RES, V12, P293
[7]   VEGF Signaling through Neuropilin 1 Guides Commissural Axon Crossing at the Optic Chiasm [J].
Erskine, Lynda ;
Reijntjes, Susan ;
Pratt, Thomas ;
Denti, Laura ;
Schwarz, Quenten ;
Vieira, Joaquim M. ;
Alakakone, Bennett ;
Shewan, Derryck ;
Ruhrberg, Christiana .
NEURON, 2011, 70 (05) :951-965
[8]   Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity A Prospective Case-Control Study [J].
Fan, Yuan-Yao ;
Huang, Yu-Shu ;
Huang, Chung-Ying ;
Hsu, Jen-Fu ;
Shih, Chia-Pang ;
Hwang, Yih-Shiou ;
Yao, Tsung-Chieh ;
Lai, Chi-Chun ;
Wu, Wei-Chi .
OPHTHALMOLOGY, 2019, 126 (11) :1567-1577
[9]   Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity [J].
Gunay, Murat ;
Celik, Gokhan ;
Gunay, Betul Onal ;
Aktas, Alev ;
Karatekin, Guner ;
Ovali, Fahri .
ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2015, 78 (05) :300-304
[10]   Laser treatment for retinopathy of prematurity [J].
Houston, Samuel K. ;
Wykoff, Charles C. ;
Berrocal, Audina M. ;
Hess, Ditte J. ;
Murray, Timothy G. .
LASERS IN MEDICAL SCIENCE, 2013, 28 (02) :683-692
123